ESTRO 2025 - Abstract Book

S1693

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

A total of 118 patients met the criteria and were included. Of these, 55 patients were treated with DRT, 31 with PreRT and 32 with PoRT. For the entire cohort, the male to female ratio was 1.16 and the median age was 16 years . The median follow up time was 2.25 years .. At 2 years the OS was 87.95% (CI 81.48%-94.94%) , LC was 93.47%(CI 88.53%-98.68%) , PFS was 74.98% (CI 66.86%-84.1%) for the entire cohort. Within individual cohorts, OS at 2 years was 85.26 % for DRT, 89.29% for PreRT and 91.67% for PoRT (p=0.60) . LC at 2 years was 90.17% for DRT, 100% for PreRT and at 4 years was 92.64% for PoRT (p=0.085) . PFS at 2 years was 68.25% for DRT, and at 4 years was 79.31% for PreRT and 82.78% for PoRT (p=0.61) . The commonest radiation related toxicities were radiation dermatitis with RTOG grade 3 & above seen in 28/118(23.7%) patients and oral mucositis grade 3 & above in 2/11 ( 18%) patients who received radiotherapy to head and neck.